Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022

Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany

Johanna Erber, Verena Kappler, Bernhard Haller, Hrvoje Mijočević, Ana Galhoz, Clarissa Prazeres da Costa, Friedemann Gebhardt, Natalia Graf, Dieter Hoffmann, Markus Thaler, Elke Lorenz, Hedwig Roggendorf, Florian Kohlmayer, Andreas Henkel, Michael P. Menden, Jürgen Ruland, Christoph D. Spinner, Ulrike Protzer1, Percy Knolle1, Paul Lingor1Comments to Author , and on behalf of the SeCoMRI Study Group2
Author affiliations: University Hospital rechts der Isar, Munich, Germany (J. Erber, V. Kappler, B. Haller, H. Mijočević, C. Prazeres da Costa, F. Gebhardt, N. Graf, D. Hoffmann, M. Thaler, H. Roggendorf, F. Kohlmayer, A. Henkel, J. Ruland, C.D. Spinner, U. Protzer, P. Knolle, P. Lingor); German Center for Infection Research, Munich (J. Erber, D. Hoffmann, J. Ruland, U. Protzer, C.D. Spinner); Helmholtz Zentrum München-German, Neuherberg, Germany (A. Galhoz, M.P. Menden); Ludwig-Maximilians University Munich, Martinsried, Germany (A. Galhoz, M.P. Menden); German Center for Diabetes Research, Neuherberg (M.P. Menden); Technical University of Munich, Munich (M.P. Menden)

Main Article

Table 3

Seroprevalence of SARS-CoV-2 IgG in patients and staff, by symptom onset and frequency, at a university hospital, Munich, Germany*

Characteristic SARS-CoV-2IgG, no. (%)
Odds ratio (95% CI)
Negative Positive
Symptom onset
Not applicable, n = 3,373 3,336 (98.9) 37 (1.1) Referent
Past 14 days, n = 219 209 (95.4) 10 (4.6) 4.36 (2.02–8.59)
Past 3‒8 weeks, n = 943 883 (93.6) 60 (6.4) 6.11 (4.05–9.35)
Unknown, n = 19

Symptom frequency, p<0.001
0, n = 3,273 3,245 (99.1) 28 (0.9) Referent
1–4, n = 548 529 (96.5) 19 (3.5) 4.17 (2.27–7.50)
5–8, n = 491 454 (92.5) 37 (7.5) 9.42 (5.72–15.70)
9–14, n = 223 200 (89.7) 23 (10.3) 13.32 (7.45–23.58)
Unknown, n = 19 18 1

*SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

1These authors contributed equally to this article.

2Members of the SeCOMRI study group are listed at the end of this article.

Page created: December 15, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.